5 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 2 | Terminated 2 |
Follow Recurrent Non-Small Cell Lung Carcinoma: new trials by email Literature Review of Recurrent Non-Small Cell Lung Carcinoma trials Research Report on Recurrent Non-Small Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer Nivolumab, Plinabulin - ALK Gene Translocation, EGFR Activating Mutation | Phase 1 / Phase 2 | Terminated | University of Washington | 5 | 2017-06-14 | 2019-03-04 |
| Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis - EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 19 | 2017-03-10 | 2024-06-28 |
| Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide - Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 11 | 2015-05-22 | 2021-09-13 |
| Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Azacitidine, Docetaxel, Entinostat - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 17 | 2013-05-01 | 2018-07-27 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Bevacizumab, Carboplatin, Cixutumumab - Large Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 175 | 2010-03-01 | 2018-06-06 |
Carcinoma, Non-Small-Cell Lung (5) · Adenocarcinoma of Lung (1) · Mesothelioma, Malignant (1)
Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Lung Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Adenoma (1) · Carcinoma (1) · Mesothelioma (1)
Nivolumab (2) · Adjuvants, Immunologic (1) · Azacitidine (1) · Bevacizumab (1) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Drug Therapy (1) · Gemcitabine (1) · Immunotherapy (1) · Irinotecan (1) · Molecular Targeted Therapy (1) · NPI 2358 (1) · Paclitaxel (1) · Pemetrexed (1)
National Cancer Institute (NCI) (2) · Fred Hutchinson Cancer Center (1) · University of Washington (1) · Wake Forest University Health Sciences (1)
United States (5)
Julie Brahmer (1) · Rafael Santana-Davila (1) · Sylvia Lee (1) · William Petty (1)
P30CA015704 (2), P30CA006973 (1), P30CA012197 (1), U10CA021115 (1), U10CA180820 (1)